All patients receiving treatment for their haemophilia with clotting factors or currently marketed bispecific antibodies mimicking the function of clotting factor VIII.
All patients receiving treatment for their haemophilia with clotting factors or currently marketed bispecific antibodies mimicking the function of clotting factor VIII.